Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Quick urine test could spot HIV pill problems before virus rebounds

NCT ID NCT05333679

Knowledge-focused Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new urine-based rapid test (UTRA) that checks if people with HIV are taking their medication tenofovir as prescribed. The goal is to catch adherence problems early, before the virus level in blood rises. Researchers compared the urine test results with blood drug levels, self-reports, and pharmacy records in 200 participants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
urine tenofovir rapid assay (UTRA) test
What this could lead to
If successful, this test could help clinics identify adherence problems early and provide timely support, keeping HIV suppressed.
What could go wrong
This is a completed study with 200 participants, so results are limited in size and may not apply to all settings. The test only checks for one medication (tenofovir) and may miss other adherence issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

200 people

The number who actually took part.

Started

Mar 2022

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥18 years old * Willing and able to provide written informed consent * HIV-infected, receiving or (re-)starting a tenofovir-based ART regimen * Current ART regimen includes at least one drug with a high genetic barrier to resistance e.g. dolutegravir, atazanavir/ritonavir, darunavir/ritonavir or lopinavir/ritonavir. * Any previous raised viral load \>50 copies/ml (after ART initiation). * Willing and able to comply with laboratory tests and other study procedures Exclusion Criteria: * Not willing or able to provide informed consent in any of the languages provided * Not receiving a tenofovir-based ART regimen * Any other clinical condition that in the opinion of an investigator puts the patient at increased risk if participating in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease Risk Reduction Behavior

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Risk reduction

Contacts and locations

Locations

  • Desmond Tutu Health Foundation, University of Cape Town

    Cape Town, Western Cape, 7925, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.